P-915 - Borderline personality disorder significantly improved when treated with 18 mg per day of Paliperidone ER: a case report - 13/06/12
Résumé |
Introduction |
Paliperidone ER recommended therapeutic range is between 3 – 12mg once daily. In this poster presentation we will describe a case in which, for self-medication, therapeutic efficacy was achieved at higher doses.
Methods |
Mr. M.G. is a thirty-nine year old man that lives with his parents and has a diagnosis of borderline personality disorder (DSM-IV-TR) presenting paranoid ideation, instability, impulsivity, emptiness, sexual promiscuity, drugs consumption.
During the last hospitalization in his referral of Psychiatry unit (May 2011), routine blood tests were within normal range; at discharge in the community, Paliperidone ER 9mg/day was prescribed. At the first out-patient visit, as the clinical picture appeared unchanged the psychiatrist continued with the same therapy. At the second check-up, severity of symptoms was reduced, and M.G. reported to have taken for more than a month, on his own initiative, the double dose of Paliperidone ER (18mg per day divided into two daily intakes); as the therapy was effective and well tolerated the psychiatrist chose to continue with the same therapy at the same dosage.
After 4 months (September 2011) the clinical picture is further enhanced.
Results |
At each stage the client was assessed using: CGI (stage-one=6,4,09; stage-two=6,4,09; stage-three=4,1,05; stage-four=4,1,01), BPRS (95-94-62-41), HDRS (33-33-15-2), HARS (48-40-14-1), SOFAS (25-30-55-60), PSP (25-30-61-70); BPDSI: 476 at the admission, 163 actually.
Conclusions |
This study highlights the case of the patient in achieving a significant improvement in symptoms at a dose of Paliperidone above the upper limit of the recommended range. Further studies are required.
Le texte complet de cet article est disponible en PDF.Vol 27 - N° S1
P. 1 - 2012 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
